25 XP   0   0   10

Abcellera Biologics Inc
Buy, Hold or Sell?

Let's analyse Abcellera together

PenkeI guess you are interested in Abcellera Biologics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Abcellera Biologics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Abcellera Biologics Inc

I send you an email if I find something interesting about Abcellera Biologics Inc.

Quick analysis of Abcellera (30 sec.)










What can you expect buying and holding a share of Abcellera? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
16.7%

What is your share worth?

Current worth
$3.94
Expected worth in 1 year
$4.01
How sure are you?
83.3%

+ What do you gain per year?

Total Gains per Share
$0.07
Return On Investment
2.0%

For what price can you sell your share?

Current Price per Share
$3.78
Expected price per share
$0 - $4.31
How sure are you?
50%

1. Valuation of Abcellera (5 min.)




Live pricePrice per Share (EOD)

$3.78

Intrinsic Value Per Share

$-4.20 - $-1.33

Total Value Per Share

$-0.27 - $2.60

2. Growth of Abcellera (5 min.)




Is Abcellera growing?

Current yearPrevious yearGrowGrow %
How rich?$1.1b$1.2b-$80.9m-7.0%

How much money is Abcellera making?

Current yearPrevious yearGrowGrow %
Making money-$146.3m$158.5m-$304.9m-208.3%
Net Profit Margin-385.0%32.7%--

How much money comes from the company's main activities?

3. Financial Health of Abcellera (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#50 / 1007

Most Revenue
#299 / 1007

Most Profit
#839 / 1007

Most Efficient
#705 / 1007

What can you expect buying and holding a share of Abcellera? (5 min.)

Welcome investor! Abcellera's management wants to use your money to grow the business. In return you get a share of Abcellera.

What can you expect buying and holding a share of Abcellera?

First you should know what it really means to hold a share of Abcellera. And how you can make/lose money.

Speculation

The Price per Share of Abcellera is $3.78. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Abcellera.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Abcellera, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.94. Based on the TTM, the Book Value Change Per Share is $0.02 per quarter. Based on the YOY, the Book Value Change Per Share is $0.69 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Abcellera.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.50-13.2%-0.50-13.2%0.5013.3%0.184.7%0.153.9%
Usd Book Value Change Per Share0.020.5%0.020.5%0.6918.4%0.7820.6%0.6617.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.020.5%0.020.5%0.6918.4%0.7820.6%0.6617.4%
Usd Price Per Share5.71-5.71-10.13-14.08-11.73-
Price to Earnings Ratio-11.42--11.42-20.12-27.49-22.91-
Price-to-Total Gains Ratio309.64-309.64-14.58-93.91-93.91-
Price to Book Ratio1.45-1.45-2.59-4.53-3.78-
Price-to-Total Gains Ratio309.64-309.64-14.58-93.91-93.91-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.78
Number of shares264
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.020.78
Usd Total Gains Per Share0.020.78
Gains per Quarter (264 shares)4.87205.72
Gains per Year (264 shares)19.47822.87
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101990823813
203928016461636
305847024692459
407866032913282
509785041144105
60117104049374928
70136123057605751
80156142065836574
90175161074067397
100195180082298220

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%2.01.00.066.7%3.02.00.060.0%4.02.00.066.7%4.02.00.066.7%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%5.01.00.083.3%5.01.00.083.3%
Dividend per Share0.00.01.00.0%0.00.03.00.0%1.00.04.020.0%1.00.05.016.7%1.00.05.016.7%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%5.01.00.083.3%5.01.00.083.3%

Fundamentals of Abcellera

About Abcellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets, as well as strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Fundamental data was last updated by Penke on 2024-05-02 09:03:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Abcellera Biologics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Abcellera earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Abcellera to the Biotechnology industry mean.
  • A Net Profit Margin of -385.0% means that $-3.85 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Abcellera Biologics Inc:

  • The MRQ is -385.0%. The company is making a huge loss. -2
  • The TTM is -385.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-385.0%TTM-385.0%0.0%
TTM-385.0%YOY32.7%-417.7%
TTM-385.0%5Y-68.2%-316.8%
5Y-68.2%10Y-56.3%-12.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-385.0%-207.2%-177.8%
TTM-385.0%-218.5%-166.5%
YOY32.7%-282.4%+315.1%
5Y-68.2%-432.2%+364.0%
10Y-56.3%-593.8%+537.5%
1.1.2. Return on Assets

Shows how efficient Abcellera is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Abcellera to the Biotechnology industry mean.
  • -9.8% Return on Assets means that Abcellera generated $-0.10 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Abcellera Biologics Inc:

  • The MRQ is -9.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -9.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.8%TTM-9.8%0.0%
TTM-9.8%YOY10.3%-20.1%
TTM-9.8%5Y0.4%-10.2%
5Y0.4%10Y0.5%-0.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.8%-13.2%+3.4%
TTM-9.8%-12.6%+2.8%
YOY10.3%-11.5%+21.8%
5Y0.4%-13.7%+14.1%
10Y0.5%-15.5%+16.0%
1.1.3. Return on Equity

Shows how efficient Abcellera is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Abcellera to the Biotechnology industry mean.
  • -12.7% Return on Equity means Abcellera generated $-0.13 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Abcellera Biologics Inc:

  • The MRQ is -12.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -12.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.7%TTM-12.7%0.0%
TTM-12.7%YOY12.9%-25.6%
TTM-12.7%5Y-1.9%-10.8%
5Y-1.9%10Y-1.1%-0.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.7%-16.7%+4.0%
TTM-12.7%-15.8%+3.1%
YOY12.9%-14.4%+27.3%
5Y-1.9%-19.0%+17.1%
10Y-1.1%-19.9%+18.8%

1.2. Operating Efficiency of Abcellera Biologics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Abcellera is operating .

  • Measures how much profit Abcellera makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Abcellera to the Biotechnology industry mean.
  • An Operating Margin of -586.6% means the company generated $-5.87  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Abcellera Biologics Inc:

  • The MRQ is -586.6%. The company is operating very inefficient. -2
  • The TTM is -586.6%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-586.6%TTM-586.6%0.0%
TTM-586.6%YOY44.6%-631.2%
TTM-586.6%5Y-105.6%-481.0%
5Y-105.6%10Y-86.3%-19.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-586.6%-286.5%-300.1%
TTM-586.6%-229.1%-357.5%
YOY44.6%-288.4%+333.0%
5Y-105.6%-480.7%+375.1%
10Y-86.3%-624.7%+538.4%
1.2.2. Operating Ratio

Measures how efficient Abcellera is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 7.68 means that the operating costs are $7.68 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Abcellera Biologics Inc:

  • The MRQ is 7.678. The company is inefficient in keeping operating costs low. -1
  • The TTM is 7.678. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ7.678TTM7.6780.000
TTM7.678YOY0.532+7.146
TTM7.6785Y3.140+4.538
5Y3.14010Y2.767+0.373
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.6783.231+4.447
TTM7.6783.307+4.371
YOY0.5323.774-3.242
5Y3.1405.667-2.527
10Y2.7677.558-4.791

1.3. Liquidity of Abcellera Biologics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Abcellera is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 7.33 means the company has $7.33 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Abcellera Biologics Inc:

  • The MRQ is 7.327. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.327. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.327TTM7.3270.000
TTM7.327YOY8.667-1.340
TTM7.3275Y6.632+0.695
5Y6.63210Y5.919+0.712
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.3273.890+3.437
TTM7.3274.182+3.145
YOY8.6675.343+3.324
5Y6.6326.135+0.497
10Y5.9196.453-0.534
1.3.2. Quick Ratio

Measures if Abcellera is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Abcellera to the Biotechnology industry mean.
  • A Quick Ratio of 12.20 means the company can pay off $12.20 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Abcellera Biologics Inc:

  • The MRQ is 12.202. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 12.202. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ12.202TTM12.2020.000
TTM12.202YOY12.044+0.158
TTM12.2025Y9.733+2.469
5Y9.73310Y8.490+1.244
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.2023.528+8.674
TTM12.2024.059+8.143
YOY12.0445.390+6.654
5Y9.7336.138+3.595
10Y8.4906.488+2.002

1.4. Solvency of Abcellera Biologics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Abcellera assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Abcellera to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.23 means that Abcellera assets are financed with 22.6% credit (debt) and the remaining percentage (100% - 22.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Abcellera Biologics Inc:

  • The MRQ is 0.226. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.226. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.226TTM0.2260.000
TTM0.226YOY0.200+0.026
TTM0.2265Y0.277-0.051
5Y0.27710Y0.307-0.030
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2260.339-0.113
TTM0.2260.337-0.111
YOY0.2000.273-0.073
5Y0.2770.368-0.091
10Y0.3070.391-0.084
1.4.2. Debt to Equity Ratio

Measures if Abcellera is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Abcellera to the Biotechnology industry mean.
  • A Debt to Equity ratio of 29.1% means that company has $0.29 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Abcellera Biologics Inc:

  • The MRQ is 0.291. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.291. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.291TTM0.2910.000
TTM0.291YOY0.249+0.042
TTM0.2915Y0.466-0.174
5Y0.46610Y0.530-0.064
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2910.388-0.097
TTM0.2910.403-0.112
YOY0.2490.342-0.093
5Y0.4660.432+0.034
10Y0.5300.461+0.069

2. Market Valuation of Abcellera Biologics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Abcellera generates.

  • Above 15 is considered overpriced but always compare Abcellera to the Biotechnology industry mean.
  • A PE ratio of -11.42 means the investor is paying $-11.42 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Abcellera Biologics Inc:

  • The EOD is -7.560. Based on the earnings, the company is expensive. -2
  • The MRQ is -11.419. Based on the earnings, the company is expensive. -2
  • The TTM is -11.419. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.560MRQ-11.419+3.860
MRQ-11.419TTM-11.4190.000
TTM-11.419YOY20.119-31.538
TTM-11.4195Y27.486-38.906
5Y27.48610Y22.905+4.581
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.560-2.249-5.311
MRQ-11.419-2.553-8.866
TTM-11.419-2.669-8.750
YOY20.119-4.107+24.226
5Y27.486-6.247+33.733
10Y22.905-6.499+29.404
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Abcellera Biologics Inc:

  • The EOD is -9.117. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -13.773. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -13.773. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-9.117MRQ-13.773+4.655
MRQ-13.773TTM-13.7730.000
TTM-13.773YOY15.580-29.353
TTM-13.7735Y299.166-312.939
5Y299.16610Y249.305+49.861
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-9.117-2.858-6.259
MRQ-13.773-3.288-10.485
TTM-13.773-3.552-10.221
YOY15.580-5.560+21.140
5Y299.166-8.326+307.492
10Y249.305-8.881+258.186
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Abcellera is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.45 means the investor is paying $1.45 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Abcellera Biologics Inc:

  • The EOD is 0.960. Based on the equity, the company is cheap. +2
  • The MRQ is 1.451. Based on the equity, the company is underpriced. +1
  • The TTM is 1.451. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.960MRQ1.451-0.490
MRQ1.451TTM1.4510.000
TTM1.451YOY2.586-1.135
TTM1.4515Y4.532-3.081
5Y4.53210Y3.777+0.755
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.9601.929-0.969
MRQ1.4512.090-0.639
TTM1.4512.091-0.640
YOY2.5862.881-0.295
5Y4.5323.545+0.987
10Y3.7773.936-0.159
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Abcellera Biologics Inc.

3.1. Institutions holding Abcellera Biologics Inc

Institutions are holding 45.322% of the shares of Abcellera Biologics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Baillie Gifford & Co Limited.8.21250.108824044796-2159853-8.2423
2023-12-31Baker Bros Advisors LP7.82481.488522909753214643010.3376
2023-12-31ING Investment Management LLC3.62870.07251062418500
2023-12-31Capital World Investors2.85240.00858351293-69200-0.8218
2023-12-31Credit Suisse First Boston (CSFB)1.56370.0252457825052730.1153
2023-12-31Orbimed Advisors, LLC1.42790.4768418076800
2023-12-31ArrowMark Colorado Holdings, LLC (ArrowMark Partners)1.40210.2587410509500
2023-12-31BlackRock Inc1.3340.0006390571349626714.5556
2023-12-31Founders Fund VII Management, LLC1.288989.827377353000
2023-12-31Lazard Asset Management LLC1.16540.024734120052651728.4266
2023-12-31Federated Hermes Inc1.06480.04423117680-136673-4.1997
2023-12-31Casdin Capital, LLC0.80611.3228236012900
2023-12-31Fidelity International Ltd0.64070.0113187587218758720
2023-12-31Guardian Capital Advisors LP0.61021.112178641400
2023-12-31Prosight Management, LP0.58063.89711700000-746000-30.4988
2023-12-31Renaissance Technologies Corp0.49850.01291459503-232550-13.7437
2023-12-31Millennium Management LLC0.42870.00311255219-266060-17.4892
2023-12-31Goldman Sachs Group Inc0.41070.00061202482943186363.7488
2023-12-31Novo A/S0.38490.3974112691500
2023-12-31Two Sigma Investments LLC0.36520.0141069238-128234-10.7087
Total 36.490899.1067106838840+1993630+1.9%

3.2. Funds holding Abcellera Biologics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Allianz Global Artfcl Intlgc W EUR2.09690.39376139452-12331-0.2004
2023-12-31American Funds SMALLCAP World A1.87170.0435548000000
2024-02-29Baillie Gifford Positive Change1.83440.95115370852-332665-5.8326
2024-02-29Baillie Gifford Positive Change B Acc1.83430.95175370488-431188-7.4321
2024-02-29CS (Lux) Digital Health Equity SB USD1.5371.4591450000000
2023-09-25SMDS Global AI Equity Mother1.53370.52064490520-135005-2.9187
2024-02-29Baillie Gifford WW Pstv Chg B USD Acc1.16240.96413403284-144630-4.0765
2023-12-31American Funds IS® Asset Allocation 10.98070.0638287129300
2024-03-28iShares Biotechnology ETF0.52850.0919154741100
2023-12-31Lazard Global Small Cap Equity0.44151.077812926321147399.741
2024-02-29ACATIS Datini Valueflex Fonds A0.34160.5861100000000
2023-11-20Nissay Glb Digital Hlthcare Equity MF0.33272.889397400014970018.1609
2023-11-20Nissay Glbl Digital Hlthcare Eq MF0.33272.889397400014970018.1609
2024-02-29Baillie Gifford Global Discovery A Acc0.32730.6539958227-25241-2.5665
2023-12-31Lazard Digital Health0.32253.294944285528725.9313
2023-12-31Edinburgh Worldwide Ord0.31370.5219918480-1616-0.1756
2023-11-30Baillie Gifford International Alpha 20.28540.176183545500
2023-12-31Mediolanum BB Global Impact L0.18970.3337555383-177049-24.1728
2023-12-31BrighthouseII Baillie Gifford Intl Stk A0.18640.205954583000
2024-02-29BlackRock Global Equity Mkt Netrl Instl0.18140.2052531176222514.3722
Total 16.634518.272748702768-770463-1.6%

3.3. Insider Transactions

Insiders are holding 27.98% of the shares of Abcellera Biologics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-05-26Andrew BoothBUY145006.85
2023-05-26Holdings Ltd. ThermopylaeBUY1530006.52

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Abcellera Biologics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0180.0180%0.695-97%0.779-98%0.656-97%
Book Value Per Share--3.9363.9360%3.917+0%2.789+41%2.331+69%
Current Ratio--7.3277.3270%8.667-15%6.632+10%5.919+24%
Debt To Asset Ratio--0.2260.2260%0.200+13%0.277-19%0.307-27%
Debt To Equity Ratio--0.2910.2910%0.249+17%0.466-37%0.530-45%
Dividend Per Share----0%-0%0.000-100%0.000-100%
Eps---0.500-0.5000%0.504-199%0.177-383%0.148-439%
Free Cash Flow Per Share---0.415-0.4150%0.650-164%0.169-346%0.140-397%
Free Cash Flow To Equity Per Share---0.379-0.3790%0.645-159%0.639-159%0.539-170%
Gross Profit Margin--1.0971.0970%0.929+18%1.217-10%0.797+38%
Intrinsic Value_10Y_max---1.332--------
Intrinsic Value_10Y_min---4.204--------
Intrinsic Value_1Y_max--0.186--------
Intrinsic Value_1Y_min--0.020--------
Intrinsic Value_3Y_max--0.316--------
Intrinsic Value_3Y_min---0.321--------
Intrinsic Value_5Y_max--0.152--------
Intrinsic Value_5Y_min---1.079--------
Market Cap1106716020.480-51%1671785311.3601671785311.3600%3189200093.150-48%4238828260.630-61%3532356883.858-53%
Net Profit Margin---3.850-3.8500%0.327-1279%-0.682-82%-0.563-85%
Operating Margin---5.866-5.8660%0.446-1415%-1.056-82%-0.863-85%
Operating Ratio--7.6787.6780%0.532+1343%3.140+145%2.767+177%
Pb Ratio0.960-51%1.4511.4510%2.586-44%4.532-68%3.777-62%
Pe Ratio-7.560+34%-11.419-11.4190%20.119-157%27.486-142%22.905-150%
Price Per Share3.780-51%5.7105.7100%10.130-44%14.076-59%11.730-51%
Price To Free Cash Flow Ratio-9.117+34%-13.773-13.7730%15.580-188%299.166-105%249.305-106%
Price To Total Gains Ratio204.981-51%309.641309.6410%14.581+2024%93.908+230%93.908+230%
Quick Ratio--12.20212.2020%12.044+1%9.733+25%8.490+44%
Return On Assets---0.098-0.0980%0.103-196%0.004-2825%0.005-1920%
Return On Equity---0.127-0.1270%0.129-199%-0.019-85%-0.011-91%
Total Gains Per Share--0.0180.0180%0.695-97%0.779-98%0.656-97%
Usd Book Value--1152318000.0001152318000.0000%1233277000.000-7%850417630.000+36%710616225.500+62%
Usd Book Value Change Per Share--0.0180.0180%0.695-97%0.779-98%0.656-97%
Usd Book Value Per Share--3.9363.9360%3.917+0%2.789+41%2.331+69%
Usd Dividend Per Share----0%-0%0.000-100%0.000-100%
Usd Eps---0.500-0.5000%0.504-199%0.177-383%0.148-439%
Usd Free Cash Flow---121384000.000-121384000.0000%204700000.000-159%55232365.400-320%45736637.833-365%
Usd Free Cash Flow Per Share---0.415-0.4150%0.650-164%0.169-346%0.140-397%
Usd Free Cash Flow To Equity Per Share---0.379-0.3790%0.645-159%0.639-159%0.539-170%
Usd Market Cap1106716020.480-51%1671785311.3601671785311.3600%3189200093.150-48%4238828260.630-61%3532356883.858-53%
Usd Price Per Share3.780-51%5.7105.7100%10.130-44%14.076-59%11.730-51%
Usd Profit---146398000.000-146398000.0000%158519000.000-192%25281682.400-679%21119568.667-793%
Usd Revenue--38025000.00038025000.0000%485424000.000-92%155965417.200-76%131443014.333-71%
Usd Total Gains Per Share--0.0180.0180%0.695-97%0.779-98%0.656-97%
 EOD+2 -6MRQTTM+0 -0YOY+9 -255Y+12 -2410Y+13 -23

4.2. Fundamental Score

Let's check the fundamental score of Abcellera Biologics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-7.560
Price to Book Ratio (EOD)Between0-10.960
Net Profit Margin (MRQ)Greater than0-3.850
Operating Margin (MRQ)Greater than0-5.866
Quick Ratio (MRQ)Greater than112.202
Current Ratio (MRQ)Greater than17.327
Debt to Asset Ratio (MRQ)Less than10.226
Debt to Equity Ratio (MRQ)Less than10.291
Return on Equity (MRQ)Greater than0.15-0.127
Return on Assets (MRQ)Greater than0.05-0.098
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Abcellera Biologics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5036.100
Ma 20Greater thanMa 504.087
Ma 50Greater thanMa 1004.486
Ma 100Greater thanMa 2004.924
OpenGreater thanClose3.770
Total0/5 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-12-312020-12-312021-12-312022-12-312023-12-31
Income Tax Expense  20938,70638,91526,77065,68514,89580,580-108,211-27,631



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,488,094
Total Liabilities335,776
Total Stockholder Equity1,152,318
 As reported
Total Liabilities 335,776
Total Stockholder Equity+ 1,152,318
Total Assets = 1,488,094

Assets

Total Assets1,488,094
Total Current Assets871,985
Long-term Assets616,109
Total Current Assets
Cash And Cash Equivalents 133,320
Short-term Investments 627,265
Net Receivables 64,382
Inventory 1,107
Other Current Assets 20,911
Total Current Assets  (as reported)871,985
Total Current Assets  (calculated)846,985
+/- 25,000
Long-term Assets
Property Plant Equipment 287,696
Goodwill 47,806
Long Term Investments 65,938
Intangible Assets 120,425
Long-term Assets Other 94,244
Long-term Assets  (as reported)616,109
Long-term Assets  (calculated)616,109
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities119,013
Long-term Liabilities216,763
Total Stockholder Equity1,152,318
Total Current Liabilities
Short-term Debt 6,158
Accounts payable 25,509
Other Current Liabilities 61,276
Total Current Liabilities  (as reported)119,013
Total Current Liabilities  (calculated)92,943
+/- 26,070
Long-term Liabilities
Capital Lease Obligations 77,380
Long-term Liabilities Other 5,906
Long-term Liabilities  (as reported)216,763
Long-term Liabilities  (calculated)83,286
+/- 133,477
Total Stockholder Equity
Common Stock753,199
Retained Earnings 279,787
Accumulated Other Comprehensive Income -1,720
Other Stockholders Equity 121,052
Total Stockholder Equity (as reported)1,152,318
Total Stockholder Equity (calculated)1,152,318
+/-0
Other
Capital Stock753,199
Cash and Short Term Investments 760,585
Common Stock Shares Outstanding 289,166
Current Deferred Revenue26,070
Liabilities and Stockholders Equity 1,488,094
Net Debt -55,940
Net Invested Capital 1,152,318
Net Working Capital 752,972
Property Plant and Equipment Gross 318,304
Short Long Term Debt Total 77,380



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
> Total Assets 
21,492
23,488
1,005,536
1,318,569
1,540,907
1,488,094
1,488,0941,540,9071,318,5691,005,53623,48821,492
   > Total Current Assets 
15,162
12,640
813,325
929,800
1,025,491
871,985
871,9851,025,491929,800813,32512,64015,162
       Cash And Cash Equivalents 
10,444
7,553
594,116
476,142
386,535
133,320
133,320386,535476,142594,1167,55310,444
       Short-term Investments 
0
0
594,116
246,835
499,950
627,265
627,265499,950246,835594,11600
       Net Receivables 
4,168
4,378
213,239
160,576
38,593
64,382
64,38238,593160,576213,2394,3784,168
       Other Current Assets 
550
1,811
5,970
21,247
75,413
20,911
20,91175,41321,2475,9701,811550
   > Long-term Assets 
6,330
10,848
192,211
388,769
515,416
616,109
616,109515,416388,769192,21110,8486,330
       Property Plant Equipment 
6,330
8,480
17,923
111,616
217,255
287,696
287,696217,255111,61617,9238,4806,330
       Goodwill 
0
0
31,500
47,806
47,806
47,806
47,80647,80647,80631,50000
       Long Term Investments 
0
0
19,247
50,313
72,522
65,938
65,93872,52250,31319,24700
       Intangible Assets 
0
0
115,153
148,392
131,502
120,425
120,425131,502148,392115,15300
       Other Assets 
0
2,368
8,388
30,642
84,431
0
084,43130,6428,3882,3680
> Total Liabilities 
9,883
13,236
175,028
292,836
307,630
335,776
335,776307,630292,836175,02813,2369,883
   > Total Current Liabilities 
6,433
7,895
103,490
120,676
118,320
119,013
119,013118,320120,676103,4907,8956,433
       Short-term Debt 
2,531
2,886
190
3,652
5,583
6,158
6,1585,5833,6521902,8862,531
       Short Long Term Debt 
2,531
2,467
190
0
0
0
0001902,4672,531
       Accounts payable 
1,518
1,643
20,005
32,017
33,150
25,509
25,50933,15032,01720,0051,6431,518
       Other Current Liabilities 
50
129
76,706
77,471
57,975
61,276
61,27657,97577,47176,70612950
   > Long-term Liabilities 
3,450
5,341
71,538
172,160
189,310
216,763
216,763189,310172,16071,5385,3413,450
       Long term Debt 
911
1,363
2,198
0
0
0
0002,1981,363911
       Capital Lease Obligations 
0
3,061
3,715
36,413
82,258
77,380
77,38082,25836,4133,7153,0610
       Other Liabilities 
2,538
1,336
65,625
134,014
112,635
0
0112,635134,01465,6251,3362,538
       Long-term Liabilities Other 
277
0
4,422
134,790
3,086
5,906
5,9063,086134,7904,4220277
       Deferred Long Term Liability 
0
0
0
37,370
33,178
0
033,17837,370000
> Total Stockholder Equity
11,609
10,252
830,508
1,025,733
1,233,277
1,152,318
1,152,3181,233,2771,025,733830,50810,25211,609
   Common Stock
5,074
5,122
710,387
722,430
734,365
753,199
753,199734,365722,430710,3875,1225,074
   Retained Earnings Total Equity
0
0
0
267,666
426,185
0
0426,185267,666000
   Accumulated Other Comprehensive Income 
-1,553
-3,157
0
280
-1,391
-1,720
-1,720-1,3912800-3,157-1,553
   Capital Surplus 
0
0
0
35,357
74,118
0
074,11835,357000
   Treasury Stock000000
   Other Stockholders Equity 
3,036
2,300
5,919
35,357
74,118
121,052
121,05274,11835,3575,9192,3003,036



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue38,025
Cost of Revenue-30,894
Gross Profit7,1317,131
 
Operating Income (+$)
Gross Profit7,131
Operating Expense-261,077
Operating Income-237,207-253,946
 
Operating Expense (+$)
Research Development175,658
Selling General Administrative60,999
Selling And Marketing Expenses14,180
Operating Expense261,077250,837
 
Net Interest Income (+$)
Interest Income42,247
Interest Expense-0
Other Finance Cost-0
Net Interest Income42,247
 
Pretax Income (+$)
Operating Income-237,207
Net Interest Income42,247
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-174,029-243,983
EBIT - interestExpense = -223,052
-174,029
-146,398
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-223,052-174,029
Earnings Before Interest and Taxes (EBITDA)-192,158
 
After tax Income (+$)
Income Before Tax-174,029
Tax Provision--27,631
Net Income From Continuing Ops-146,398-146,398
Net Income-146,398
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses261,077
Total Other Income/Expenses Net6,776-42,247
 

Technical Analysis of Abcellera
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Abcellera. The general trend of Abcellera is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Abcellera's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Abcellera Biologics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 4.248 < 4.27 < 4.31.

The bearish price targets are: .

Tweet this
Abcellera Biologics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Abcellera Biologics Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Abcellera Biologics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Abcellera Biologics Inc. The current macd is -0.22120142.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Abcellera price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Abcellera. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Abcellera price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Abcellera Biologics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAbcellera Biologics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Abcellera Biologics Inc. The current adx is 20.73.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Abcellera shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Abcellera Biologics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Abcellera Biologics Inc. The current sar is 4.02071528.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Abcellera Biologics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Abcellera Biologics Inc. The current rsi is 36.10. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -3/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
Abcellera Biologics Inc Daily Relative Strength Index (RSI) ChartAbcellera Biologics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Abcellera Biologics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Abcellera price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Abcellera Biologics Inc Daily Stochastic Oscillator ChartAbcellera Biologics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Abcellera Biologics Inc. The current cci is -82.41230942.

Abcellera Biologics Inc Daily Commodity Channel Index (CCI) ChartAbcellera Biologics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Abcellera Biologics Inc. The current cmo is -27.9599792.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Abcellera Biologics Inc Daily Chande Momentum Oscillator (CMO) ChartAbcellera Biologics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Abcellera Biologics Inc. The current willr is -80.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Abcellera is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Abcellera Biologics Inc Daily Williams %R ChartAbcellera Biologics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Abcellera Biologics Inc.

Abcellera Biologics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Abcellera Biologics Inc. The current atr is 0.22800933.

Abcellera Biologics Inc Daily Average True Range (ATR) ChartAbcellera Biologics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Abcellera Biologics Inc. The current obv is 38,213,306.

Abcellera Biologics Inc Daily On-Balance Volume (OBV) ChartAbcellera Biologics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Abcellera Biologics Inc. The current mfi is 34.54.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Abcellera Biologics Inc Daily Money Flow Index (MFI) ChartAbcellera Biologics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Abcellera Biologics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-14ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-16BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-26RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-30WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Abcellera Biologics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Abcellera Biologics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5036.100
Ma 20Greater thanMa 504.087
Ma 50Greater thanMa 1004.486
Ma 100Greater thanMa 2004.924
OpenGreater thanClose3.770
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Abcellera with someone you think should read this too:
  • Are you bullish or bearish on Abcellera? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Abcellera? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Abcellera Biologics Inc

I send you an email if I find something interesting about Abcellera Biologics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Abcellera Biologics Inc.

Receive notifications about Abcellera Biologics Inc in your mailbox!